Premature Ejaculation Cured With A Spray

both men and women reporting a greater satisfaction with their sex lives

A new clinical trial for treatment to help men suffering from premature ejaculation has shown impressive results. The trials which were done in America for a topically applied anesthetic considerably increased the time to ejaculation which could lead to a commercial application for the spray. Plethora Solutions of London together with Sciele Pharma Inc of Atlanta, America have been researching this spray anesthetic named PSD502 or Tempe which is made up of lidocaine and prilocaine.   The clinical trial which was authored by Dr. Michael G. Wyllie involved over 250 men in almost 40 locations in America, Canada and Poland.

Previous to the research the average lasting time of the men was just over half a minute but when the PSD502 Spray was used the average time went up to 2 minutes 36 seconds. Interestingly when men were given a placebo spray they also reported longer average lasting times of 48 seconds. While this increase is not of much use it shows that there is a psychological aspect to premature ejaculation.

No serious adverse events were reported and the benefits of using the premature ejaculation spray continued for three months leading to both men and women reporting a greater satisfaction with their sex lives. Premature ejaculation as a medical condition can be as distressing as erectile dysfunction.  Men who suffer from premature ejaculation find it difficult to relax when having sex and women complain that everything is over too soon. As many as 30 percent of men have suffered from premature ejaculation at some point in their lives.

The results of this trial which were presented at the Sexual Medicine Society of North America have aroused interest in a number of pharmaceutical organisations who would be interested in developing the spray further so that a commercial application could be filed with both the American FDA and the European EMEA for full approval for marketing and sale.